Concepedia

Metformin use and improved response to therapy in esophageal adenocarcinoma

Heath D. Skinner, Matthew R. McCurdy, Alfredo Echeverria, Steven H. Lin, James W. Welsh, Michael S. O’Reilly, Wayne L. Hofstetter, Jaffer A. Ajani, Ritsuko Komaki, James D. Cox,

Acta Oncologica · 2012 · 110 citations · 23 references

DOIFull text

Open access

Abstract

Metformin use is associated with a dose-dependent increased response to CRT in esophageal cancer and may be a sensitizer to this therapy.

References

23

Systemic Treatment with the Antidiabetic Drug Metformin Selectively Impairs p53-Deficient Tumor Cell Growth

Monica Buzzai, Russell G. Jones, Ravi K. Amaravadi et al. · Cancer Research · 2007 · 915 citations · Full text

Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer

Sao Jiralerspong, Shana L. Palla, Sharon H. Giordano et al. · Journal of Clinical Oncology · 2009 · 872 citations · Full text

Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1

Isaam Ben Sahra, Claire Regazzetti, Guillaume Robert et al. · Cancer Research · 2011 · 611 citations

Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals

Meei-Shyuan Lee, Chih-Cheng Hsu, Mark L. Wahlqvist et al. · BMC Cancer · 2011 · 461 citations · Full text

<i>TP53</i> Disruptive Mutations Lead to Head and Neck Cancer Treatment Failure through Inhibition of Radiation-Induced Senescence

Heath D. Skinner, Vlad C. Sandulache, Thomas J. Ow et al. · Clinical Cancer Research · 2011 · 309 citations · Full text